Craig Polson
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Cholinesterase and Neurodegenerative Diseases, Drug Transport and Resistance Mechanisms, Neuroscience and Neuropharmacology Research
Most-Cited Works
- → Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027(2012)171 cited
- → Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor(2005)159 cited
- → Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models(2015)148 cited
- → Tau Overexpression Impacts a Neuroinflammation Gene Expression Network Perturbed in Alzheimer’s Disease(2014)107 cited
- → An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning(2003)99 cited
- → A new EGF-active polymeric pyridinium alkaloid from the sponge Callyspongia fibrosa(1993)97 cited
- → Inhibitors of Aβ production: solid-phase synthesis and SAR of α-hydroxycarbonyl derivatives(2003)81 cited
- → The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression(2008)66 cited
- → Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat(2012)63 cited
- → Fluorine Substitution Can Block CYP3A4 Metabolism-Dependent Inhibition: Identification of (S)-N-[1-(4-Fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an Orally Bioavailable KCNQ2 Opener Devoid of CYP3A4 Metabolism-Dependent Inhibition(2003)58 cited